MaRS Innovation is the commercialization agent for 14 of Ontario’s leading academic institutions, including the University of Toronto and its affiliated research hospitals, York University, Ryerson University and Thunder Bay Regional Health Research Institute, and is located within the MaRS Discovery District complex in Toronto, Canada. Supported by its members and industry partners, MaRS Innovation is a transformational commercialization hub that turns research strengths into commercial opportunities through strategic partnerships, licensing and company creation. MaRS Innovation represents over $1.47 billion of R&D funding annually, a portfolio of more than 60 companies, $160M in outside risk capital, and is credited with creating over 400 jobs.
For more information, please see www.marsinnovation.com
Evotec AG is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading academic institutions, pharmaceutical and biotechnology companies, patient advocacy groups and venture capitalists. Drug discovery solutions are provided in form of integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and fee-for-service work. Evotec operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure.
For more information, please see www.evotec.com